Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that it has entered into a Letter of Intent with the pan-Canadian Pharmaceutical Alliance regarding RADICAVA®, an intravenous infusion treatment for amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.
TORONTO, April 22, 2020 /CNW/ - Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that it has entered into a Letter of Intent with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding RADICAVA® (edaravone), an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS), a rapidly progressive, neurodegenerative disease.1
“This is an important milestone in our efforts to secure coverage for RADICAVA under publicly funded drug plans in Canada,” said Atsushi Fujimoto, President, MTP-CA. “We would like to thank the pCPA negotiating team for its efforts. This step allows us to commence discussions with participating provinces, territories and federal agencies across Canada, but there is more work to be done.”
With a Letter of Intent with the pCPA now in place, MTP-CA expects to enter into discussions with participating provinces, territories and federal agencies regarding the listing of RADICAVA under publicly funded drug programs.
About RADICAVA® (edaravone)
RADICAVA is indicated to slow loss of physical function as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R).2 Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) through an iterative clinical development platform over a 13-year period. In 2015, edaravone was approved for use as a treatment for ALS in Japan and South Korea. RADICAVA was approved by the U.S. Food and Drug Administration in May of 2017. Marketing authorization was granted in Canada in October 2018 and Switzerland in January 2019.
About Mitsubishi Tanabe Pharma Canada, Inc.
Based in Toronto, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) with a goal to provide therapies for some of the most difficult-to-treat diseases, including ALS. For more information, please visit www.mt-pharma-ca.com.
About Mitsubishi Tanabe Pharma America, Inc.
Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation’s (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in North America. It was established by MTPC to commercialize approved pharmaceutical products in North America with plans to expand its product line through collaborations with partners. For more information, please visit www.mt-pharma-america.com.
| 1 National Institute of Neurological Disorders and Stroke. Amyotrophic Lateral Sclerosis (ALS) Information Page |
| https://www.ninds.nih.gov/disorders/all-disorders/amyotrophic-lateral-sclerosis-als-information-page. Accessed March 2018 |
| 2 RADICAVA® (edaravone) Canada Product Monograph. October 2019 https://www.mt-pharma-ca.com/our-product/ |
SOURCE Mitsubishi Tanabe Pharma Canada, Inc.
